Another rare but tumor-specific ctDNA variant, the fibroblast growth factor receptor 2 (FGFR2) fusion gene, has been identified as a potential biomarker for monitoring treatment response in advanced ovarian cancer. Here, FGFR2 is linked to ovarian carcinoma.